Are Skybiotech Healthcare Limited latest results good or bad?
2026-06-02 19:39:02Skybiotech Healthcare Limited's latest financial results for Q4 FY26 present a mixed picture, highlighting both operational challenges and some signs of revenue recovery. The company reported net sales of ₹1.83 crores, which reflects a significant quarter-on-quarter increase of 90.63%. However, this growth comes after a previous decline, indicating volatility in revenue generation. Year-on-year, the revenue also shows a notable increase of 79.41% compared to ₹1.02 crores in Q4 FY25. Despite the revenue growth, the company's operational struggles are evident. Skybiotech recorded a net loss of ₹0.30 crores, which is a 37.50% decline from the previous quarter's loss. The operating margin remains deeply negative at -48.09%, suggesting ongoing difficulties in converting sales into profits. The company has now reported negative operating profits for seven consecutive quarters, indicating persistent operational d...
Read full news article
Skybiotech Healthcare Q4 FY26: Mounting Losses Signal Deepening Operational Crisis
2026-06-01 14:35:15Skybiotech Healthcare Limited, a micro-cap textile manufacturer with a market capitalisation of ₹28.00 crores, reported a net loss of ₹0.30 crores for Q4 FY26, marking the seventh consecutive quarter of losses despite a sharp revenue uptick. The stock surged 5.00% on June 01, 2026, closing at ₹152.25, though this represents a 35.84% decline from its 52-week high of ₹237.30.
Read full news articleAre Skybiotech Healthcare Limited latest results good or bad?
2026-05-30 19:54:23Skybiotech Healthcare Limited's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported net sales of ₹0.96 crores, reflecting a year-on-year decline of 61.90% from ₹2.52 crores in Q3 FY25, and a quarter-on-quarter contraction of 50.00% from ₹1.92 crores in Q2 FY26. This sharp revenue drop raises concerns about the company's ability to maintain sustainable client engagements or trading opportunities, especially given the previous quarter's decline of 19.67%. The net loss for the quarter was ₹0.48 crores, which represents a worsening from the loss of ₹0.31 crores in the prior quarter. The operating margin also deteriorated significantly, standing at negative 45.83%, compared to negative 11.46% in Q2 FY26. This indicates that the company's core operations are incurring substantial losses, consuming capital at an accelerating rate. Skybiotech's return on equity (...
Read full news articleWhen is the next results date for Skybiotech Healthcare Limited?
2026-05-27 23:17:59The next results date for Skybiotech Healthcare Limited is scheduled for 30 May 2026....
Read full news article
Skybiotech Healthcare Limited is Rated Strong Sell
2026-05-14 10:10:32Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Skybiotech Healthcare Limited is Rated Strong Sell
2026-04-16 10:10:16Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Dec 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 16 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news articleResults Financials For The Year Ended On 31St March 2026
30-May-2026 | Source : BSESubmission of Financial Results for the Quarter and Year ended on 31st March 2026
Board Meeting Outcome for Submission Of Outcome Of Board Meeting And Submission Of Financial Results For The Quarter And Year Ended On 31St March 2026
30-May-2026 | Source : BSESubmission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
Board Meeting Intimation for Approval Of Audited Results For The Quarter And Year Ended On March 31 2026
26-May-2026 | Source : BSESkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve Approval of Audited Results for the Quarter and Year ended on March 31 2026
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






